

CURRICULUM VITAE

Name: Scott Chasan-Taber, Ph.D.

Contact Information:

Clinical Trial Analytics, LLC
69 Mount Warner Road
Hadley, MA 01035
(413) 253-0036
sct.stats@gmail.com

Education:

University of Massachusetts, School of Public Health
Ph.D., Biostatistics 1994

University of Wisconsin - Madison
M.S., Economics, 1985

Rutgers College
B.A., Economics, 1984

London School of Economics
General Course, Economics, 1982-1983

Experience:

3/14 – Present
5/11 – 12/11
3/01 – 8/06

Principal and Biostatistician

Clinical Trial Analytics, LLC (formerly Independent Biostatistical Consultant, LLC
and Pioneer BioDiligence)
Amherst, MA

1/17 – Present
5/03 – 5/15

Academic Lecturer

Adjunct Assistant Professor

School of Public Health and Health Sciences
University of Massachusetts
Amherst, MA

1/12 – 2/16
1/12 – 2/14

Research Assistant Professor

Director, Data and Analytic Core

The Dartmouth Institute for Health Policy & Clinical Practice
Geisel School of Medicine at Dartmouth
Lebanon, NH

8/06 – 4/11	Senior Director, Biostatistics Genzyme Corporation Cambridge, MA
9/99 – 2/01	Director, Biometrics
3/97 – 8/99	Manager, Biostatistics and Statistical Programming
2/96 - 2/97	Manager, Statistical Programming
3/95 - 1/96	Biostatistician Boston Biostatistics, Inc. Framingham, MA
8/92 - 4/95	Biostatistician Harvard Medical School, Department of Health Care Policy Boston, MA
11/93 - 4/95	Visiting Research Fellow Department of Nutrition Harvard School of Public Health Boston, MA
5/89 - 8/89	Statistical Programmer Channing Laboratory Harvard Medical School Boston, MA
5/87 - 8/88	Statistical Programmer
6/84 - 8/84	Medical Data Analyst DuPont Pharmaceuticals Wilmington, DE

Affiliations/Memberships:

1993 - Present	American Statistical Association
1996 - 2002	Drug Information Association
1996 - 2001	Pharmaceutical SAS Users Group
1996 – 2011	Biometrics Society

Honors/Awards:

2001	Initiated into Delta Omega – Rho Chapter (Honors Society in Public Health)
1991 - 1992	National Public Health Service Traineeship Award
1989 - 1991	Teaching Assistant Fellowship
1988 - 1989	National Public Health Service Traineeship Award
1983	Initiated into Omicron Delta Epsilon (Honor Society in Economics)

Publications:

1. Alousi A, Yao B, Overman B, Ratanatharathorn V, Gill S, Socie G, Dai Y, **Chasan-Taber S**, Anderson K, Mujeebuddin A, Champlin R, Shpall E, Holtan S. Phase 2A Study of ALXN1007, a Novel C5a Inhibitor, in Subjects With Newly Diagnosed Acute Graft-Versus-Host Disease (GVHD) Involving the Lower Gastrointestinal Tract. Proceedings of the 21st Congress of the European Hematology Association (EHA) 2016 June.
2. Johnson S, Louie TJ, Gerding DN, Cornely OA, **Chasan-Taber S**, Fitts D, Gelone SP, Broom C, Davidson DM. Vancomycin, Metronidazole, or Tolevamer for *Clostridium difficile* Infection: Results from Two Multinational, Randomized, Controlled Trials. *Clin Infect Dis*. 2014 May; 58(10).
3. McGowan MP, Tardif J-C, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, Wagener G, **Chasan-Taber S**. Randomized, placebo-controlled trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy. *PLOS ONE* 7(11): e49006.
4. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, **Chasan-Taber S**, Tribble DL, Flaim JD, Crooke ST. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. *Lancet* 2010; 375(9719):998-1006.
5. Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, **Chasan-Taber S**, Plone MA, Moe S. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. *Am J Kidney Dis*. 2010 Feb; 55(2):307-15.
6. Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, **Chasan-Taber S**, Duggal A, Fan S. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. *Nephrol Dial Transplant*. 2009 Jan;24(1):278-85.
7. Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, **Chasan-Taber S**, Heaton J, Duggal A, Kalra PA. Efficacy and Tolerability of Sevelamer Carbonate in Hyperphosphatemic Patients Who Have Chronic Kidney Disease and Are Not on Dialysis. *Clin J Am Soc Nephrol* 2008.
8. Delmez J, Block G, Robertson J, **Chasan-Taber S**, Blair A, Dillon M, Bleyer AJ. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. *Clinical Nephrology* 2007; 58:386-391.
9. Suki W, Zabaneh R, Cangiano J, Reed J, Fischer D, Garrett L, Ling B, **Chasan-Taber S**, Dillon M, Blair A, Burke S. A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients – The DCOR trial. *Nephrology Dialysis Transplantation* 2006; 21(Suppl. 4):145-146.
10. Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dew G, Weiss K, Simon S, John JF, Garber G, **Chasan-Taber S**, Davidson D. Tolevamer, a Novel Nonantibiotic Polymer, Compared With Vancomycin in the Treatment of Mild to Moderately Severe *Clostridium-difficile* - Associated Diarrhea. *Clin Infect Dis* 2006; 43:411-420.

11. Garg JP, **Chasan-Taber S**, Blair A, Plone M, Bommer J, Raggi P, Chertow GM. Effects of Sevelamer and Calcium-based Phosphate Binders on Uric Acid Concentrations in Hemodialysis Patients. Arthritis and Rheumatism 2005; 52:290-295.
12. Foster, Karen A.; **Chasan-Taber, S**; Dracker, Robert A.; Gunter, Kurt C. Comparison of umbilical cord collection methods: Impact on cellularity and microbial contamination rates. *Blood*.2005;106(11, Part 2):403B-404B.
13. Ferramosca E, Burke S, **Chasan-Taber S**, Ratti C, Chertow GM, Raggi P. Potential Antiatherogenic and Anti-Inflammatory Properties of Sevelamer in Maintenance of Hemodialysis Patients. American Heart Journal 2005;149:820-825.
14. Raggi P, James G, Burke SK, Bommer J, **Chasan-Taber S**, Holzer H, Braun J, Chertow GM. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. *Bone Miner Res.* 2005 May;20(5):764-72.
15. Chertow GM, Raggi P, **Chasan-Taber S**, Bommer J, Holzer H, Burke SK. Determinants of Progressive Vascular Calcification in Hemodialysis Patients. *Nephrol. Dial. Transplant.* (2004) 19 (6): 1489-1496.
16. Raggi, Paolo; Burke, Steven K.; **Chasan-Taber, S**; Blair, Andrew T.; Chertow, Glenn M.; Holzer, Herwig; Bommer, Juergen. The severity of coronary and aortic calcification is inversely related to trabecular bone density. *Journal of the American Society of Nephrology.* 14(Abstracts Issue) 2003; 694A.
17. Chasan-Taber L, Erickson JB, **Chasan-Taber S**, Nasca P, Freedson PS. Validity and reproducibility of a physical activity questionnaire in women. Med Sci Sports Exerc 2002; 34:987-992.
18. Chasan-Taber L, Erickson JB, McBride JW, Nasca PC, **Chasan-Taber S**, Freedson PS. Reproducibility of a self-administered lifetime physical activity questionnaire among female college alumnae. Am J Epidemiol 2002; 155:282-289.
19. Raggi P, Boulay A, **Chasan-Taber S**, Amin N, Dillon M, Burke SK, Chertow GM. Cardiac Calcification in Adult Hemodialysis Patients: A Link between ESRD and Cardiovascular Disease? *J Am Coll Cardiol* 2002; 39:695-701.
20. Weissman JS, Ayanian JZ, **Chasan-Taber S**, Sherwood MJ, Roth C, Epstein AM. Hospital Readmissions and Quality of Care. Medical Care 1999; 37:490-501.
21. Ayanian JZ, Weissman JS, **Chasan-Taber S**, Epstein AM. Quality of care by race and gender for congestive heart failure and pneumonia. *Medical Care.*1999;37(12):1260-9.
22. Ayanian JZ, Weissman JS, **Chasan-Taber S**, Epstein AM. Quality of Care for Two Common Illnesses in Teaching and Non-Teaching Hospitals. Health Affairs 1998; 17:194-205.
23. Schiffer F, Zaidel E, Bogen J, **Chasan-Taber S**. Differential Psychological Status in the Two Hemispheres of Two Split-Brain Patients. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1998; 11:151-156.
24. Barnett ML, Kremer JM, St. Clair EW, Clegg DO, Furst D, Weisman M, Fletcher MJF, **Chasan-Taber S**, Finger E, Morales A, Le CH, Trentham DE. Treatment of Rheumatoid Arthritis with Oral Type II Collagen: Results of a Multicenter, Double-blind, Placebo-controlled Trial. Arthritis & Rheumatism 1998;.41:290-297.

25. **Chasan-Taber S**, Rimm EB, Stampfer MJ, Spiegelman D, Colditz G, Giovannucci E, Ascherio A, Willett WC. Reproducibility and Validity of a Self-Administered Physical Activity Questionnaire for Male Health Professionals. Epidemiology 1996; 7:81-86.
26. Weissman JS, Cleary PD, Seage GR, Gatsonis C, Haas JS, **Chasan-Taber S**, Epstein AM. The Influence of Health-Related Quality of Life and Social Characteristics on Hospital Use by Patients With AIDS. Medical Care 1996; 34:1037-1054.
27. Weissman JS, Levin K, **Chasan-Taber S**, Massagli MP, Seage GR, Scampini L, Epstein AM. The Validity of Self-Reported Health Care Utilization by AIDS Patients AIDS 1996; 10:775-783.
28. Hosmer DW, **Taber SM**, Lemeshow S. The Importance of Assessing the Fit of Logistic Regression Models: A Case Study. American Journal of Public Health 1991; 81:1630-1635.
29. Lemeshow S, **Taber SM**. Lot Quality Assurance Sampling: Single and Double Sampling Plans. World Health Statistics Quarterly 1991; 44:115-132.

Presentations:

- August 2014 "Bias Reduction in the Design and Analysis of Imaging Studies"
Joint Statistical Meetings
- June 1995 "Reproducibility and Validity of a Self-Administered Physical Activity Questionnaire for Male Health Professionals"
Society for Epidemiologic Research Annual Meeting
- April 1994 "Comparison of Non-Nested Logistic Models"
Department of Biostatistics
Harvard School of Public Health
- October 1993 "Risk-of-Readmission Adjustment in Studies Evaluating Hospital Readmission Patterns"
Department of Health Care Policy
Harvard Medical School
- June 1993 "An Introduction to ROC Curve Analysis"
Department of Health Care Policy
Harvard Medical School